Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects ≥12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Next Previous
Trial Profile

A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects ≥12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary) ; Lamotrigine; Levetiracetam
  • Indications Generalised seizures; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Acronyms Study 512
  • Sponsors Eisai Co Ltd

Most Recent Events

  • 14 Aug 2023 According to a Catalyst Pharmaceuticals media release, design of this study will be presented at the upcoming 35th International Epilepsy Congress taking place on September 2 - 6, 2023 in Dublin, Ireland
  • 08 Feb 2023 Status changed from active, no longer recruiting to completed.
  • 10 Jan 2023 Planned End Date changed from 31 Dec 2022 to 9 Feb 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top